ArticleStem cell research & therapy2025
Human dental pulp stem cell-derived mitochondria restore mitochondrial function and promote neuroregeneration in a cellular model of Parkinson's disease.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons, primarily due to mitochondrial dysfunction. Current treatments focus on managing symptoms but are unable to regenerate neurons. Human dental pulp stem cells (hDPSCs) offer a promising source for neurodegenerative therapy due to their accessibility and neuro-supportive properties. However, research on the mitochondrial characteristics of hDPSCs and their therapeutic potential remains limited. This study investigates the capacity of mitochondria isolated from hDPSCs to restore mitochondrial function and promote neuronal recovery and function in a PD cellular model.
methodshDPSCs were isolated and characterized for mesenchymal stem cell properties. Mitochondria were isolated, quantified, and assessed for viability and morphology using MitoTracker staining and transmission electron microscopy. Mitochondrial uptake and functional recovery were evaluated in a PD cellular model using MPP⁺-treated differentiated SH-SY5Y cells. Mitochondrial function was assessed by measuring Complex I activity, ATP production, and reactive oxygen species (ROS) levels. Neuroregeneration and synaptic function were analyzed through neurite length, growth-associated protein 43 (GAP43) and tyrosine hydroxylase (TH), Synaptophysin (SYP), dopamine transporter (DAT), calcium imaging, and mitochondrial dynamics.
resultsIsolated hDPSC-derived mitochondria were mostly viable, spherical, and displayed immature cristae. In MPP⁺-treated SH-SY5Y cells, mitochondrial transfer restored Complex I activity, elevated ATP production, and reduced ROS. Treated cells also showed significantly longer neurites and increased expression of GAP43, TH, SYP, and DAT. Calcium imaging revealed restored intracellular calcium responses upon stimulation. Mitochondria from hDPSCs localized in both cell bodies and neurites and remained distinct from damaged host mitochondria, supporting synaptic function.
conclusionsMitochondria derived from hDPSCs can restore bioenergetic function, reduce oxidative stress, and promote structural and functional recovery in a PD cellular model. These findings highlight the foundational therapeutic potential of hDPSC-derived mitochondria as a regenerative approach for neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.